Roles of serum total P-cresylsulfate and chronic kidney disease in coronary atherosclerotic burden in acute coronary syndrome patients

Acta Cardiologica Sinica

Volumn 28, Issue 4, 2012, Pages 297-305

  Wang, Chao Ping ^a,f   Lu, Li Fen ^c   Tsai, I Ting ^e   Yang, Chih Ying ^e   Yu, Teng Hung ^a   Hung, Wei Chin ^a   Chiu, Cheng An ^a   Hsu, Chia Chang ^b   Chen, Han Jung ^d   Houng, Jer Yiing ^f  

^a Division of Cardiology   (Taiwan)

^b Division of Gastroenterology   (Taiwan)

^c Division of Cardiac Surgery   (Taiwan)

^d Division of Neurology   (Taiwan)

^e E DA HOSPITAL   (Taiwan)

^f I SHOU UNIVERSITY   (Taiwan)

Author keywords

Acute coronary syndrome; Chronic kidney disease; Coronary atherosclerotic burden; Total p cresylsulfate

Indexed keywords

PARA CRESOL; PARA CRESYLSULFATE; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 84872741398     PISSN: 10116842     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305.
2. Dohi T, Miyauchi K, Okazaki S, et al. Long-term impact of mild chronic kidney disease in patients with acute coronary syndrome undergoing percutaneous coronary interventions. Nephrol Dial Transplant 2011;26:2906-11.
3. Jourde-Chiche N, Dou L, Cerini C, et al. Protein-bound toxinsupdate 2009. Semin Dial 2009;22:334-9.
4. Vanholder R, Argilés A, Baurmeister U, et al. Uremic toxicity: present state of the art. Int J Artif Organs 2001;24:695-725. (Pubitemid 33121206)
5. Glorieux G, Cohen G, Jankowski J, Vanholder R. Platelet/leukocyte activation, inflammation, and uremia. Semin Dial 2009; 22:423-7.
6. Martinez AW, Recht NS, Hostetter TH, Meyer TW. Removal of p-cresol sulfate by hemodialysis. J Am Soc Nephro 2005;16: 3430-6. (Pubitemid 46187553)
7. de Loor H, Bammens B, Evenepoel P, et al. Gas chromatographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum. Clin Chem 2005;51:1535-8. (Pubitemid 41060897)
8. De Smet R, David F, Sandra P, et al. Asensitive HPLC method for the quantification of free and total p-cresol in patients with chronic renal failure. Clin Chim Acta 1998;278:1-21. (Pubitemid 28544982)
9. Schepers E, Meert N, Glorieux G, et al. P-cresylsulphate, the main in vivo metabolite of pcresol, activates leucocyte free radical production. Nephrol Dial Transplant 2007;22:592-6. (Pubitemid 46189906)
10. Wang CP, Lu LF, Yu TH, et al. Serum levels of total p-cresylsulphate are associated with angiographic coronary atherosclerosis severity in stable angina patients with early stage of renal failure. Atherosclerosis 2010;211:579-83.
11. Dubey L, Zeng H, Hashmi S, et al. Association of plasma leptin levels and complexity of the culprit lesion in patients with unstable angina. Int J Cardiol 2008;126:183-9. (Pubitemid 351602098)
12. Liu SW, Qiao SB, Yuan JS, Liu DQ. Association of plasma visfatin levels with inflammation, atherosclerosis, and acute coronary syndromes in humans. Clin Endocrinol (Oxf) 2009;71: 202-7.
13. White HD, Chew DP. Acute myocardial infarction. Lancet 2008;372:570-84.
14. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Commit-tee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36:959-69.
15. Chung FM, Tsai JCR, Chang DM, et al. Peripheral total and differential leukocyte count in diabetic nephropathy: the relationship of plasma leptin to leukocytosis. Diabetes Care 2005;28:1710-7.
16. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 2006;354:2473-83. (Pubitemid 43855050)
17. Hanna EB, Chen AY, Roe MT, et al. Characteristics and inhospital outcomes of patients with non-ST-segment elevation myocardial infarction and chronic kidney disease undergoing percutaneous coronary intervention. JACC Cardiovasc Interv 2011;4:1002-8.
18. Deanfield J, Donald A, Ferri C, et al. Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005;23:7-17.
19. Dou L, Bertrand E, Cerini C, et al. The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int 2004;65:442-51. (Pubitemid 38130638)
20. Vanholder R, Massy Z, Argiles A, et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005;20:1048-56. (Pubitemid 40862092)
21. Meijers BK, Van Kerckhoven S, Verbeke K, et al. The Uremic retention solute p-cresyl sulfate and markers of endothelial damage. Am J Kidney Dis 2009;54:891-901.
22. Chiu CA, Lu LF, Yu TH, et al. Increased levels of total pcresylsulphate and indoxyl sulphate are associated with coronary artery disease in patients with diabetic nephropathy. Rev Diabet Stud 2010;7:275-84.
23. Liabeuf S, Barreto DV, Barreto FC, et al. European Uraemic Toxin Work Group (EUTox). Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant 2010;25:1183-91.
24. Wu IW, Hsu KH, Hsu HJ, et al. Serum free p-cresyl sulfate levels predict cardiovascular and all-cause mortality in elderly hemodialysis patients-a prospective cohort study. Nephrol Dial Transplant 2012;27:1169-75.
25. Levey AS, Atkins R, Coresh J, et al. Chronic kidney disease as a global public health problem: approaches and initiatives: a position statement from Kidney Disease Improving Global Outcomes. Kidney Int 2007;72:247-59. (Pubitemid 47172384)
26. Meguid El, Nahas A, Bello AK. Chronic kidney disease: the global challenge. Lancet 2005;365:331-40. (Pubitemid 40139112)
27. Brunet P, Gondouin B, Duval-Sabatier A, et al. Does uremia cause vascular dysfunction? Kidney Blood Press Res 2011;34: 284-90.
28. Wang CP, Lu LF, Yu TH, et al. Associations among chronic kidney disease, high total p-cresylsulfate and major adverse cardiac events. J Nephrol 2012 Mar 23:0. doi: 10.5301/jn.5000111. [Epub ahead of print]
29. Lemos KF, Davis R, Moraes MA, Azzolin K. Prevalence of risk factors for acute coronary syndrome in patients treated in an emergency service. Rev Gaucha Enferm 2010;31:129-35.
30. Simonenko VB, Shoimu EA, Dem'ianenko AV. Risk factor structure and specific clinical features of acute coronary syndrome in aged and elderly patients. Klin Med (Mosk) 2009;87:17-20.
31. Al-Rasadi K, Al-Zakwani I, Zubaid M, et al. Prevalence, predictors, and impact of low high-density lipoprotein cholesterol on in-hospital outcomes among acute coronary syndrome patients in the middle east. Open Cardiovasc Med J 2011;5:203-9.
32. Hsu HP, Jou YL, Lin SJ, et al. Comparison of in-hospital outcome of acute ST elevation myocardial infarction in patients with versus without diabetes mellitus. Acta Cardiol Sin 2011;27:145-51.
33. Hartopo AB, Gharini PP, Setianto BY. Low serum albumin levels and in-hospital adverse outcomes in acute coronary syndrome. Int Heart J 2010;51:221-6.
34. Kiyosue A, Hirata Y, Ando J, et al. Relationship between renal dysfunction and severity of coronary artery disease in Japanese patients. Circ J 2010;74:786-91